X4 Pharmaceuticals
XFOR
98 hedge funds and large institutions have $58.9M invested in X4 Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 35 increasing their positions, 19 reducing their positions, and 17 closing their positions.
232% more call options, than puts
Call options by funds: $349K | Put options by funds: $105K
84% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 19
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
2% more funds holding
Funds holding: 96 → 98 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.03% less ownership
Funds ownership: 2.04% → 2.02% (-0.03%)
59% less capital invested
Capital invested by funds: $143M → $58.9M (-$84.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.12M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$1.25M |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$718K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$622K |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$533K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$3.35M |
| 2 |
Morgan Stanley
New York
|
-$1.28M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.19M |
| 4 |
Goldman Sachs
New York
|
-$968K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$822K |
XFOR Hedge Fund Activity: Q2 2024 in Review
98 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2024, worth a combined $58.9M — down 59% from $143M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new XFOR positions and 17 closed out — a net gain of 2 holders — while 35 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock, adding an estimated $2.12M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $3.35M sold.
- 98 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2024, up from 96 in Q1 2024.
- Funds reported $58.9M of X4 Pharmaceuticals stock for Q2 2024, down 59% quarter-over-quarter.
- 19 funds opened new X4 Pharmaceuticals positions in Q2 2024 and 17 closed out, a net change of +2 holders.
- The largest X4 Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $2.12M added.
- The largest X4 Pharmaceuticals seller in Q2 2024 was Avidity Partners Management, an estimated $3.35M sold.
Based on aggregated 13F filings for Q2 2024.